

Appendix A

Appendix A

Full text of a single interaction with ChatGPT version 3.5. User input text is presented in bolded italics, while ChatGPT responses are in plain text.

You are a Medical Doctor. A 68 Year Old Man Comes to Your Office with a PSA Level of 11. What Diagnostic Tests Would You Like to Order?

As a medical doctor, if a 68-year-old man comes to my office with a PSA level of 11 ng/mL, I would order further diagnostic tests to evaluate his prostate health and determine if he has prostate cancer. The following tests would be useful in making a diagnosis:

1. **Digital Rectal Exam (DRE):** A doctor examines the prostate by inserting a gloved finger into the rectum to feel for any abnormalities, such as lumps or hardening of the prostate gland.
2. **Transrectal Ultrasound (TRUS):** This test uses sound waves to create images of the prostate gland. It is often used in conjunction with a biopsy to locate suspicious areas for sampling.
3. **Prostate Biopsy:** This procedure involves removing small samples of tissue from the prostate gland with a needle. The samples are then examined under a microscope for signs of cancerous cells.
4. **MRI (magnetic Resonance Imaging):** This imaging test uses a powerful magnet and radio waves to create detailed images of the prostate gland. It can help identify the size and location of any tumors.
5. **CT (Computed Tomography) Scan or Bone Scan:** These tests may be ordered if there is suspicion that the cancer has spread beyond the prostate gland.

It is important to note that an elevated PSA level does not necessarily mean that a person has prostate cancer, as there are many other factors that can affect PSA levels. Therefore, the combination of several diagnostic tests is necessary to confirm a diagnosis.

You perform a Digital Rectal Exam and the Patient's Prostate is Smooth Without Irregularity. A Transrectal Ultrasound and Prostate Biopsy are Performed. Of the 12 Biopsy Cores, 7 have Prostate Adenocarcinoma with a Gleason Grade Group of 3. MRI of the Pelvis is Obtained and is Nor-

mal. Do you Want any more Information or Diagnostic Tests before Providing a Treatment Recommendation?

Based on the information provided, a diagnosis of prostate cancer with a Gleason grade group of 3 has been made. The MRI of the pelvis is normal, which is a good sign that the cancer has not spread beyond the prostate gland. However, additional information would be helpful to guide treatment recommendations. The following tests or information could be considered:

1. **DPSA Velocity:** A measure of the rate at which PSA levels change over time. A rapid increase in PSA levels may indicate a more aggressive cancer.
2. **Imaging of the Prostate and Surrounding Tissues:** Additional imaging tests, such as a prostate-specific membrane antigen (PSMA) PET scan or a CT scan of the abdomen and pelvis, may provide further information on the size and location of the tumor, as well as if there are any signs of spread beyond the prostate gland.
3. **Patient Comorbidities:** A review of the patient's overall health status, including any comorbidities, such as heart disease or diabetes, can help guide treatment recommendations.

Based on this information, a multidisciplinary team consisting of a urologist, radiation oncologist, and medical oncologist can determine the best treatment plan for the patient. Treatment options may include surgery to remove the prostate gland, radiation therapy, or a combination of both. Additionally, the patient's overall health status and personal preferences should be considered when making treatment recommendations.

The Patient with a PSA of 11 has a Normal Rectal Exam, a TRUS Biopsy Finding 7 out of 12 Cores with Gleason Grade Group 3 Prostate Adenocarcinoma, a Normal MRI of the Pelvis, and a Normal Bone Scan. What are the Patient's Prostate Cancer Prognostic Stage and Risk Group?

Based on the information provided, we can determine the patient's prostate cancer prognostic stage and risk group using the American Joint Committee on Cancer (AJCC) staging system and National Comprehensive Cancer Network (NCCN) risk classification system.

Prognostic Stage: The patient's cancer is clinically classified as stage T1c (based on elevated PSA levels and biopsy findings), and there is no evidence of regional lymph node or distant metastasis on imaging studies. Therefore, the patient's prostate cancer is categorized as stage II according to the AJCC staging system.

Risk Group: The NCCN risk group classification system is based on several factors, including PSA level, biopsy findings, and clinical stage. Based on the information provided, the patient's NCCN risk group is intermediate risk, which is defined as having one or more of the following characteristics:

- PSA level between 10 and 20 ng/mL
- Biopsy findings with a Gleason score of 7 (grade group 2-3)
- Clinical stage T2b (cancer involves more than half of one lobe but not both lobes).

The patient has a PSA level of 11 ng/mL and biopsy findings of 7 out of 12 cores with Gleason grade group 3 (which is equivalent to Gleason score 7), which places him in the intermediate-risk group. Overall, the patient's prognosis will depend on several factors, including his age, overall health, and response to treatment. It is important for the patient to discuss treatment options with a multidisciplinary team of healthcare professionals, including a urologist, radiation oncologist, and medical oncologist, to determine the most appropriate treatment plan.

Is the Patient's Risk group Favorable Intermediate or Unfavorable Intermediate?

Based on the information provided, the patient's NCCN risk group is intermediate risk. However, it is important to determine whether the patient's risk group is favorable intermediate or unfavorable intermediate, as this information can help guide treatment decisions. The patient has a PSA level of 11 ng/mL and biopsy findings of 7 out of 12 cores with Gleason grade group 3 (which is equivalent to Gleason score 7), which places him in the intermediate-risk group. To determine if the patient's risk group is favorable or unfavorable intermediate, we need to consider additional factors, such as:

- **Age:** Older age is associated with worse outcomes in prostate cancer.
- **PSA Velocity:** A rapid increase in PSA levels over time may indicate a more aggressive cancer.
- **Percentage of Biopsy Cores Involved:** A higher percentage of biopsy cores involved with cancer is associated with worse outcomes.
- **Clinical Stage:** The extent of the cancer, as determined by clinical stage, can affect prognosis.

Without additional information, it is difficult to definitively classify the patient's risk group as favorable or unfavorable intermediate.

However, based on the information provided, the patient's risk group is likely closer to favorable intermediate, as his PSA level is relatively low, and the cancer appears to be confined to the prostate gland based on imaging studies. However, the patient's overall health status and personal preferences should also be considered when making treatment recommendations. It is important for the patient to discuss treatment options with a multidisciplinary team of healthcare professionals to determine the most appropriate treatment plan.

You are a Urologist. What Treatment Options would you Provide to this Patient?

As a urologist, there are several treatment options that I would discuss with this patient, which may include:

1. **Active Surveillance:** For some patients with low-risk or favorable intermediate-risk prostate cancer, active surveillance may be a reasonable option. This involves monitoring the cancer with regular PSA tests, digital rectal exams, and repeat biopsies, and delaying treatment until the cancer shows signs of progression.
2. **Surgery:** Radical prostatectomy, which involves removing the entire prostate gland, may be recommended for patients with intermediate-risk prostate cancer. This treatment is typically recommended for patients with a life expectancy of greater than 10 years and who have a life expectancy that is longer than the time required for recovery from surgery.
3. **Radiation Therapy:** External beam radiation therapy (EBRT) or brachytherapy (implantation of radioactive seeds into the prostate gland) may be recommended for patients with intermediate-risk prostate cancer. Radiation therapy is typically recommended for patients with a life expectancy of greater than 10 years.
4. **Combination Therapy:** For some intermediate-risk prostate cancer patients, a combination of surgery and radiation therapy may be recommended to increase the chance of curing the cancer.
5. **Androgen Deprivation Therapy (ADT):** ADT is a form of hormone therapy that reduces the levels of male hormones (androgens), which can cause prostate cancer cells to grow. ADT may be used in combination with radiation therapy for intermediate-risk prostate cancer patients.

The optimal treatment plan for this patient will depend on several factors, including his age, overall health, life expectancy, and personal preferences. It is important to discuss the potential benefits and risks of each treatment option with the patient to help them make an informed decision. Additionally, a multidisciplinary team approach, involving a urologist, radiation oncologist, and medical oncologist, can help guide treatment decisions and provide the best possible care for the patient.

You are a Radiation Oncologist and See this Patient in your Office. The Patient has Unfavorable Intermediate Risk Prostate Cancer and has Completed his Staging Work-Up, Showing no Evidence of Prostate Cancer Outside of the Prostate. The Patient would like Combination Therapy with External beam Radiation Therapy and Androgen Deprivation Therapy. What Radiation Dose and Fractionation would you Recommend?

For patients with unfavorable intermediate risk prostate cancer who receive external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT), a radiation dose of 78 Gy in 39 fractions over approximately 8 weeks is the standard of care based on results from multiple randomized clinical trials. The use of ADT in combination with radiation therapy has been shown to improve disease-free survival and overall survival in patients with intermediate and high-risk prostate cancer. The radiation dose and fractionation can be adjusted depending on several factors, including the patient's age, overall health status, and treatment-related toxicities. In some cases, a higher radiation dose of up to 80 Gy in 40 fractions may be considered in patients with higher-risk disease, although this can increase the risk of side effects such as urinary and bowel toxicity. It is important to discuss the potential benefits and risks of radiation therapy and ADT with the patient, including potential side effects such as fatigue, erectile dysfunction, and hot flashes. Additionally, the patient's overall health status, personal preferences, and the availability of radiation therapy and ADT resources should be considered when developing an individualized treatment plan.

How Many Months of Androgen Deprivation Therapy would you Recommend?

The duration of androgen deprivation therapy (ADT) in combination with radiation therapy for intermediate-risk prostate cancer is a topic of ongoing research and debate. The standard duration of ADT in combination with radiation therapy is currently 18-36 months based on the results of several clinical trials, although some studies have suggested that longer durations of ADT may provide additional benefits. For patients with unfavorable intermediate risk prostate cancer, a duration of 24-36 months of ADT is often recommended in combination with radiation therapy. However, the optimal duration of ADT should be individualized based on the patient's risk profile, age, overall health status, and personal preferences. It is important to discuss the potential benefits and risks of ADT with the patient, including potential side effects such as hot flashes, decreased libido, erectile dysfunction, and osteoporosis. Additionally, the patient's overall health status, personal preferences, and the availability of ADT resources should be considered when developing an individualized treatment plan.

When Treating this Unfavorable Intermediate Risk Prostate Adenocarcinoma Patient with External Beam Radiation, how would you Design your Treatment Volume?

When designing the treatment volume for external beam radiation therapy (EBRT) for unfavorable intermediate-risk prostate adenocarcinoma, a combination of pelvic and prostate-only radiation fields is typically used. The pelvic radiation field is used to treat the pelvic lymph nodes and may include the external iliac, internal iliac, and obturator lymph node regions. The prostate-only radiation field is used to treat the prostate gland itself. The pelvic radiation field is typically used for patients with intermediate- or high-risk prostate cancer, as there is a risk of microscopic spread of the cancer cells to the pelvic lymph nodes. However, the use of pelvic radiation can increase the risk of side effects such as bowel and bladder toxicity. The prostate-only radiation field may be used for patients with low-risk prostate cancer, as the risk of spread to the pelvic lymph nodes is low. However, for patients with unfavorable intermediate-risk prostate cancer, a combination of pelvic and prostate-only radiation fields is typically used to reduce the risk of recurrence. The specific design of the radiation fields will depend on the patient's individual anatomy and the location of the prostate gland relative to the pelvic lymph nodes. A CT scan or MRI may be used to help guide the radiation planning process and ensure that the treatment volume is accurately targeted while minimizing radiation exposure to surrounding healthy tissue.

You Decide to Treat this Patient's Prostate to 78 Gy in 39 Fractions and Decide to also use a Pelvic Radiation Field to Treat the Pelvic Lymph Nodes. What Dose and Fractionation do you Prescribe to the Pelvic Radiation Field?

When treating the pelvic lymph nodes in combination with prostate radiation therapy for unfavorable intermediate-risk prostate cancer, the standard dose and fractionation is 45 Gy in 25 fractions over approximately 5 weeks. However, the optimal dose and fractionation for pelvic radiation therapy in this setting is still an area of active research and may depend on various factors such as the patient's individual risk profile, overall health status, and the potential for treatment-related side effects. It is important to discuss the potential benefits and risks of pelvic radiation therapy with the patient, including potential side effects such as bowel and bladder toxicity. Additionally, the patient's individual anatomy and tumor characteristics should be considered when developing an individualized treatment plan. Ultimately, the specific dose and fractionation for pelvic radiation therapy should be determined on a case-by-case basis by the radiation oncologist in consultation with the patient and other members of the multidisciplinary care team.

What Radiation Treatment Technique would you use when Treating this Patient with External Beam Radiation?

When treating a patient with external beam radiation therapy (EBRT) for prostate cancer, several radiation treatment techniques can be used, including three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT). IMRT and VMAT are ad-

vanced radiation techniques that allow for the delivery of high doses of radiation to the prostate while minimizing radiation exposure to surrounding healthy tissue. These techniques use computer-controlled linear accelerators to deliver radiation beams that are shaped to conform to the shape of the prostate gland and spare nearby organs such as the bladder and rectum. IMRT uses multiple radiation beams that are delivered at different intensities and angles, while VMAT uses a single radiation beam that rotates around the patient, allowing for more precise and efficient delivery of radiation. In general, IMRT and VMAT have been shown to have similar clinical outcomes for prostate cancer and are associated with low rates of toxicity. The choice of radiation technique will depend on the patient's individual anatomy, the location of the prostate gland relative to surrounding organs, and other factors such as treatment time and resource availability. In this case, either IMRT or VMAT could be used to deliver the prescribed radiation dose to the prostate and pelvic lymph nodes while minimizing radiation exposure to surrounding healthy tissue.

The Patient asks about Proton Radiation Therapy. Would you Recommend Proton Radiation Therapy Instead of either IMRT or VMAT?

Proton radiation therapy is an advanced radiation treatment that uses high-energy proton beams to deliver radiation doses to cancerous tissue. Proton therapy has the ability to deliver a highly conformal radiation dose to the target area while minimizing radiation exposure to surrounding healthy tissue, potentially reducing the risk of treatment-related side effects. However, proton therapy is a relatively new and expensive treatment modality that may not be widely available or covered by all insurance plans. Additionally, the long-term clinical outcomes of proton therapy for prostate cancer are still being studied, and it is not yet clear whether proton therapy provides any additional benefits compared to other radiation treatment techniques. Therefore, while proton therapy is an option for some patients with prostate cancer, it is not necessarily recommended over IMRT or VMAT in all cases. The choice of radiation technique will depend on the patient's individual situation and the expertise and resources available at the treatment center. As a radiation oncologist, my recommendation for the patient would be based on various factors such as the location of the prostate gland relative to surrounding organs, the patient's medical history, and other patient-specific factors. We would discuss the potential benefits and risks of proton therapy versus other radiation treatment techniques and come to a decision that is best for the individual patient.

The Patient asks you to Describe how Proton Radiation Therapy is Different than Photon Radiation Therapy. How do you Answer the Patient?

Proton radiation therapy and photon radiation therapy are both forms of external beam radiation therapy (EBRT) used to treat cancer. However, there are some important differences between the two tech-

niques. Photon radiation therapy, which includes 3D-CRT, IMRT, and VMAT, uses high-energy X-rays to deliver radiation to the cancerous tissue. The X-rays pass through the body and deposit their energy in the tumor as well as in the surrounding healthy tissue. To minimize the exposure of healthy tissue to radiation, photon radiation therapy uses sophisticated computer algorithms and techniques to shape the radiation beam and target the tumor as precisely as possible. Proton radiation therapy, on the other hand, uses high-energy protons to deliver radiation to the tumor. Protons have a unique physical property called the Bragg peak, which allows them to deposit most of their energy at a specific depth within the tissue, with a sharp drop-off in energy beyond that point. This means that proton therapy can deliver a highly conformal radiation dose to the tumor while minimizing radiation exposure to surrounding healthy tissue, potentially reducing the risk of side effects. However, proton therapy is a newer and more complex technology compared to photon radiation therapy. Proton therapy requires specialized equipment and expertise, and is typically more expensive than photon radiation therapy. Additionally, proton therapy may not be appropriate for all types of cancer or all patients.

In summary, while photon radiation therapy and proton radiation therapy are both forms of external beam radiation therapy, proton therapy offers a unique physical advantage that can result in a more conformal radiation dose to the tumor while potentially reducing radiation exposure to surrounding healthy tissue. However, the choice of radiation technique will depend on the individual patient's situation and the resources available at the treatment center.

When Designing External Beam Radiation Treatment to the Prostate and Pelvic Lymph Nodes for this Unfavorable Intermediate Risk Prostate Adenocarcinoma Patient, What are the Most Important Organs at Risk to Consider? What Dosimetric Constraints would you Place on these Organs at Risk?

When designing external beam radiation therapy (EBRT) to the prostate and pelvic lymph nodes, there are several organs at risk that need to be carefully considered. The most important organs at risk include the rectum, bladder, and femoral heads. For the rectum, the dosimetric constraints typically include limiting the maximum dose to less than 75 Gy, and limiting the volume of rectum receiving more than 70 Gy (V70) to less than 15%. For the bladder, the constraints may include limiting the maximum dose to less than 80 Gy and limiting the volume of bladder receiving more than 65 Gy (V65) to less than 30%. For the femoral heads, the constraints may include limiting the mean dose to less than 45 Gy and limiting the volume of the femoral heads receiving more than 50 Gy (V50) to less than 50%. It's important to note that these constraints are not absolute and may vary depending on the individual patient's situation and treatment plan. The treating radiation oncologist will work with the dosimetrist and medical physicist to develop a treatment plan that balances the risk of side effects with the goal of achieving the best possible tumor control.

Can you Describe the Process of CT Simulation for this Patient?

Sure, CT simulation is an important step in the planning process for external beam radiation therapy. Here's a general overview of what happens during CT simulation:

1. **Patient Positioning:** The patient is positioned on the CT simulation table in the same position that they will be in for each treatment session. This helps to ensure accurate treatment delivery.
2. **Immobilization:** The patient may be immobilized using various devices such as a thermoplastic mask or vacuum bag to help minimize patient movement during the simulation and treatment.
3. **Imaging:** A CT scanner is used to take images of the patient in the treatment position. These images help to map out the target volume, organs at risk, and other structures that need to be included in the treatment plan.
4. **Marking:** The radiation therapists may place small marks or tattoos on the patient's skin to help ensure that the patient is positioned accurately during each treatment session.
5. **Planning:** Once the CT simulation is complete, the CT images are sent to the planning software where the radiation oncologist, dosimetrist, and medical physicist work together to develop a treatment plan that optimizes the balance between tumor control and minimizing radiation exposure to healthy tissue.
6. **Quality Assurance:** Before treatment begins, the radiation oncology team may perform quality assurance checks to ensure that the treatment plan is accurate and that the patient will receive the prescribed dose with minimal side effects.

Overall, CT simulation is a critical step in the planning process for external beam radiation therapy and helps to ensure that the patient receives accurate and effective treatment.

When Ordering CT Simulation for External Beam Radiation Treatment of this Unfavorable Intermediate Risk Prostate Adenocarcinoma Patient, Answer the Following Questions. How would you position the patient? How would you immobilize the patient? Would you use IV contrast? Would you want the patient to have a full bladder or an empty bladder? Would you want the patient to prepare their rectum?

When ordering CT simulation for external beam radiation treatment of this unfavorable intermediate risk prostate adenocarcinoma patient, here are the answers to your questions:

1. **Positioning:** The patient should be positioned on the CT simulation table in the same position that they will be in for each treatment session. For prostate treatment, the patient is typically

positioned lying on their back with their legs supported in stirrups.

2. **Immobilization:** The patient should be immobilized to minimize movement during the simulation and treatment. A thermoplastic mask or vacuum bag can be used to immobilize the patient's upper body, while a leg immobilization device can be used to immobilize the patient's legs.
3. **IV Contrast:** IV contrast is not usually necessary for prostate CT simulation.
4. **Bladder Preparation:** The patient should arrive for CT simulation with a comfortably full bladder, as this helps to push the rectum away from the prostate and reduce the risk of rectal toxicity.
5. **Rectal Preparation:** The patient should have a bowel movement prior to the CT simulation and may be instructed to use an enema or take a laxative to help ensure that the rectum is empty during treatment. Additionally, the patient may be instructed to use a rectal spacer, such as a hydrogel or balloon, to further protect the rectum during treatment. Overall, patient positioning, immobilization, and preparation are important factors to consider when ordering CT simulation for external beam radiation treatment of prostate cancer. By carefully considering these factors, the radiation oncology team can develop an accurate and effective treatment plan that minimizes side effects and maximizes tumor control.

You begin treating this patient with external beam radiation. After five weeks of treatment, the patient describes feeling like it is more difficult to initiate urination and describes a weaker urinary stream. How do you manage this complaint?

Difficulty initiating urination and a weaker urinary stream are common side effects of radiation therapy to the prostate. Here are some steps to manage this complaint:

1. **Evaluate the Patient:** The first step is to evaluate the patient to determine the cause of the urinary symptoms. A physical exam, including a digital rectal exam, can help assess the size and consistency of the prostate. A bladder scan or uroflowmetry can help evaluate the patient's urinary function.
2. **Manage Symptoms:** If the symptoms are due to radiation-induced inflammation, supportive measures such as increased hydration, a bladder relaxant medication, and/or alpha-blocker medication can be used to help manage symptoms. These medications can help relax the muscles around the prostate and improve urinary flow.
3. **Consider Referral to a Urologist:** If symptoms persist or worsen despite supportive measures, a referral to a urologist may

be necessary. The urologist can evaluate the patient's urinary function and may recommend further treatment such as a urethral dilation or medication to improve urinary function.

4. **Monitor for Other Side Effects:** It is also important to monitor the patient for other potential side effects of radiation therapy, such as rectal bleeding or diarrhea. These side effects can be managed with supportive measures such as dietary changes, medications, or a rectal spacer.

Overall, it is important to manage the patient's symptoms and evaluate for any potential complications during and after radiation therapy to the prostate. With appropriate management, most patients can successfully complete radiation therapy with minimal side effects.

How Much will this Patient's Radiation Treatment Cost in US Dollars?

The cost of radiation treatment for prostate cancer can vary widely depending on many factors, including the geographic location of the treatment center, the type of radiation therapy used, and the specifics of the individual patient's treatment plan. Other factors that may impact the cost of treatment include the duration of treatment, the need for additional imaging studies, and any additional medications or procedures required to manage side effects. It is difficult to estimate the cost of this patient's radiation treatment without more specific information about the treatment plan and location. I would recommend contacting the treatment center or the patient's insurance provider for more specific information about the cost of treatment.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2023.52.008190

Andrew B Barbour. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>